Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

A Phase III, Open-Label Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System in Elderly Subjects With Major Depression

Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression. Subjects will have study visits (clinic visits) at beginning of study (baseline) and study weeks 1, 3, 5, 8, 12, and 16.

• Men/Women in good health 65 years or older
• Ability to read, understand and sign study informed consent
• Major depression- mild to severe based on rating scale